Omega-3 Fatty Acids Predict Recurrent Venous Thromboembolism or Total Mortality in Elderly Patients with Acute Venous Thromboembolism.
Publisher DOI
PubMed ID
27790827
Abstract
BACKGROUND
The role of omega-3 fatty acids (n-3 FAs) in recurrent venous thromboembolism (VTE) remains unknown.
OBJECTIVES
To investigated the association of n-3 FAs with recurrent VTE or total mortality at six months and three years.
METHODS
N-3 FAs were assessed in 826 patients aged ≥65 years, categorized into low, medium, and high based on the 25(th) and 75(th) percentile. Mean follow up was 29 months.
RESULTS
At six months, subjects with medium (adjusted hazard ratio [HR], 0.37; 95% confidence interval [CI], 0.22 to 0.62) and high n-3 FA levels (adjusted HR, 0.36; 95% CI, 0.20 to 0.67) were less likely to develop recurrent VTE or total mortality, compared with low n-3 FAs. At three years, medium levels (adjusted HR, 0.67; 95% CI, 0.47 to 0.96) were associated with lower risk of recurrent VTE or total mortality. As compared with low n-3 FAs, the adjusted subhazard ratio [SHR] of recurrent VTE was 0.39 (95% CI, 0.15 to 0.99) in patients with medium and 0.17 (95% CI, 0.03 to 0.82) in patients with high n-3 FAs. The cumulative incidence of recurrent VTE was lower in the medium and high n-3 FA groups as compared with low n-3 FAs, but seems to have worn off after 3 years. Incidence of major and non-major bleeding was not greater in the high n-3 FA groups.
CONCLUSION
Higher levels of n-3 FA were associated with a lower risk of recurrent VTE or total mortality in elderly patients with VTE, but not with greater bleeding risk. This article is protected by copyright. All rights reserved.
The role of omega-3 fatty acids (n-3 FAs) in recurrent venous thromboembolism (VTE) remains unknown.
OBJECTIVES
To investigated the association of n-3 FAs with recurrent VTE or total mortality at six months and three years.
METHODS
N-3 FAs were assessed in 826 patients aged ≥65 years, categorized into low, medium, and high based on the 25(th) and 75(th) percentile. Mean follow up was 29 months.
RESULTS
At six months, subjects with medium (adjusted hazard ratio [HR], 0.37; 95% confidence interval [CI], 0.22 to 0.62) and high n-3 FA levels (adjusted HR, 0.36; 95% CI, 0.20 to 0.67) were less likely to develop recurrent VTE or total mortality, compared with low n-3 FAs. At three years, medium levels (adjusted HR, 0.67; 95% CI, 0.47 to 0.96) were associated with lower risk of recurrent VTE or total mortality. As compared with low n-3 FAs, the adjusted subhazard ratio [SHR] of recurrent VTE was 0.39 (95% CI, 0.15 to 0.99) in patients with medium and 0.17 (95% CI, 0.03 to 0.82) in patients with high n-3 FAs. The cumulative incidence of recurrent VTE was lower in the medium and high n-3 FA groups as compared with low n-3 FAs, but seems to have worn off after 3 years. Incidence of major and non-major bleeding was not greater in the high n-3 FA groups.
CONCLUSION
Higher levels of n-3 FA were associated with a lower risk of recurrent VTE or total mortality in elderly patients with VTE, but not with greater bleeding risk. This article is protected by copyright. All rights reserved.
Date Issued
2017-01
Publication Type
Article
Subjects
Bleeding
•
deep vein thrombosis
•
omega-3 fatty acids
•
pulmonary embolism
•
recurrent venous thromboembolism
Language(s)
en
Author(s)
Reiner, Martin F | |
Stivala, Simona | |
Bonetti, Nicole R | |
Egloff, Michael | |
von Schacky, Clemens | |
Lüscher, Thomas F | |
Camici, Giovanni G | |
Beer, Jürg H |
Journal
Journal of thrombosis and haemostasis
Publisher
Wiley-Blackwell
ISSN
1538-7836
Access(Rights)
open.access